EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Effect of Levosimendan on Ventricular Remodelling in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis

Xia Wang, Xiu-Zhi Zhao, Xi-Wen Wang, Lu-Ying Cao, Bin Lu, Zhi-Hao Wang, Wei Zhang, Yun Ti, Ming Zhong

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14714 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Xia Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, C…. Hauptthemen laut MEDLINE: Simendan, Ventricular Dysfunction, Left, Ventricular Remodeling. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Cardiovascular Multidisciplinary Integrated Research Fund, Chinese Cardiovascular Association-Access Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure is the final stage of several cardiovascular diseases, and the key to effectively treating heart failure is to reverse or delay ventricular remodelling. Levosimendan is a novel inotropic and vasodilator agent used in heart failure, whereas the impact of levosimendan on ventricular remodelling is still unclear. This study aims to investigate the impact of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction. Electronic databases were searched to identify eligible studies. A total of 66 randomized controlled trials involving 7968 patients were included. Meta-analysis results showed that levosimendan increased left ventricular ejection fraction [mean difference (MD) = 3.62, 95% confidence interval (CI) (2.88, 4.35), P < 0.00001] and stroke volume [MD = 6.59, 95% CI (3.22, 9.96), P = 0.0001] and significantly reduced left ventricular end-systolic volume [standard mean difference (SMD) = −0.52, 95% CI (−0.67, −0.37), P < 0.00001], left ventricular end-diastolic volume index [SMD = −1.24, 95% CI (−1.61, −0.86), P < 0.00001], and left ventricular end-systolic volume index [SMD = −1.06, 95% CI (−1.43, −0.70), P < 0.00001]. In terms of biomarkers, levosimendan significantly reduced the level of brain natriuretic peptide [SMD = −1.08, 95% CI (−1.60, −0.56), P < 0.0001], N-terminal pro-brain natriuretic peptide [SMD = −0.99, 95% CI (−1.41, −0.56), P < 0.00001], and interleukin-6 [SMD = −0.61, 95% CI (−0.86, −0.35), P < 0.00001]. Meanwhile, levosimendan may increase the incidence of hypotension [risk ratio (RR) = 1.24, 95% CI (1.12, 1.39), P < 0.0001], hypokalaemia [RR = 1.57, 95% CI (1.08, 2.28), P = 0.02], headache [RR = 1.89, 95% CI (1.50, 2.39), P < 0.00001], atrial fibrillation [RR = 1.31, 95% CI (1.12, 1.52), P = 0.0005], and premature ventricular complexes [RR = 1.86, 95% CI (1.27, 2.72), P = 0.001]. In addition, levosimendan reduced all-cause mortality [RR = 0.83, 95% CI (0.74, 0.94), P = 0.002]. In conclusion, our study found that levosimendan might reverse ventricular remodelling when applied in patients with left ventricular systolic dysfunction, especially in patients undergoing cardiac surgery, decompensated heart failure, and septic shock.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SimendanVentricular Dysfunction, LeftVentricular RemodelingHumansCardiotonic AgentsStroke VolumeSystoleVentricular Function, Left

Stichwörter der Autor:innen

Left ventricular systolic dysfunctionLevosimendanMeta‐analysisSafetyVentricular remodelling

Substanzen

Cardiotonic AgentsSimendan

Autor:innen und Institutionen

  • National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and C…
  • Department of Cardiology, People's Hospital of Lixia District of Jinan, Jinan, Shandong, China.
  • Department of Geriatric Medicine, Shandong Key Laboratory of Cardiovascular Proteomics, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Förderung

  • National Natural Science Foundation of China
  • Cardiovascular Multidisciplinary Integrated Research Fund
  • Chinese Cardiovascular Association-Access Fund
  • Taishan Scholars

Zitieren

APA

Wang, X., Zhao, X. Z., Wang, X. W., Cao, L. Y., Lu, B., Wang, Z. H., Zhang, W., Ti, Y., & Zhong, M. (2024). Effect of Levosimendan on Ventricular Remodelling in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis. ESC Heart Failure. https://doi.org/10.1002/ehf2.14714

Vancouver

Wang X, Zhao XZ, Wang XW, Cao LY, Lu B, Wang ZH, et al. Effect of Levosimendan on Ventricular Remodelling in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis. ESC Heart Failure. 2024. doi:10.1002/ehf2.14714

BibTeX
@article{Wang2024,
  author = {Wang, Xia and Zhao, Xiu-Zhi and Wang, Xi-Wen and Cao, Lu-Ying and Lu, Bin and Wang, Zhi-Hao and Zhang, Wei and Ti, Yun and Zhong, Ming},
  title = {Effect of Levosimendan on Ventricular Remodelling in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14714}
}
Kostenlos starten →